Citigroup Inc. has taken a significant step in the financial markets by filing a pricing supplement for its Medium-Term Senior Notes, Series N. This offering, which is linked to the performance of the Russell 2000 and S&P 500 indices, is designed to provide investors with unique opportunities while also diversifying the bank's funding sources.
The filing, dated November 12, 2026, outlines the details of the new securities, which are set to mature on November 14, 2028. Unlike conventional debt securities, these notes do not pay interest and are subject to the performance of the underlying indices. Investors may receive a return at maturity based on the performance of the worst-performing index, highlighting the risks and potential rewards associated with this type of investment.
Background
Citigroup Inc., a leading player in the national commercial banking sector, operates under the ticker symbol 'C' on the New York Stock Exchange. The company was founded in 1812 and has since grown into one of the largest financial institutions globally, providing a wide range of financial services. The recent filing is part of Citigroup's ongoing strategy to innovate and adapt to the changing financial landscape.
What the Filing Says
The pricing supplement states, "The securities offered by this pricing supplement are unsecured debt securities issued by Citigroup Global Markets Holdings Inc. and guaranteed by Citigroup Inc." It also emphasizes that these securities do not guarantee the full repayment of principal at maturity, which is a critical consideration for potential investors.
Impact
This new offering may affect a range of stakeholders, including investors looking for alternative investment vehicles, financial advisors guiding clients, and competitors in the national commercial banking industry. The unique structure of these securities may prompt other banks to explore similar offerings to remain competitive.
What's Next
The filing does not specify what happens next, but typically, the next steps would include marketing the securities to potential investors and gauging market interest before the official issue date on November 13, 2026.
Source: SEC Accession Number 0001918704-26-035346
Read Next
Q/C Technologies Enters Omnibus Amendment Agreement
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.










